Nov 20 (Reuters) - Kura Oncology KURA.O said on Wednesday it will collaborate with Japan's Kyowa Kirin 4151.T to develop and commercialize the blood cancer therapy ziftomenib.
Kura said it will receive an upfront payment of $330 million and up to $1.2 billion in total milestone payments as part of the deal.
(Reporting by Christy Santhosh in Bengaluru; Editing by Mohammed Safi Shamsi)
((Christy.Santhosh@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.